Extended Data Table 6 In tumors expressing PPARG mRNA log2[TPM + 1] > 6.1 or 7.1 (cutoffs corresponding to the provisional TPS of ≥60%), genetic alterations in PPARG, RXRA and/or FGFR3 do not provide any additional predictive value for selecting luminal lineage tumors

From: A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial

  1. Note: Log2[TPM + 1] ≥ 6.1 subset of patient population includes the Log2[TPM + 1] ≥ 7.1 subset.
Back to article page